Neurofibromatosis type 1 with comorbid optic pathway glioma does not confer additional cognitive sequelae.
In a retrospective clinical cohort of 98 pediatric patients, children with NF1 had similar cognitive performance whether or not they had optic pathway glioma, while both NF1 groups showed weaker reasoning abilities than children with non-NF1 visual-system tumors.
Open original publication →What the AI sees
In a retrospective clinical cohort of 98 pediatric patients, children with NF1 had similar cognitive performance whether or not they had optic pathway glioma, while both NF1 groups showed weaker reasoning abilities than children with non-NF1 visual-system tumors.
Research significance
The evidence supports routine neuropsychological monitoring based on NF1 status rather than OPG status alone; it may be inferred—but is not tested here—that genotype-informed surveillance could improve supportive-care targeting without assuming that the tumor independently worsens cognition.
Source abstract
OBJECTIVE: Children with neurofibromatosis type 1 (NF1) are at risk for cognitive impairments. Optic pathway gliomas (OPGs) commonly occur in children with NF1, though whether OPG exacerbates cognitive vulnerabilities beyond the NF1 genotype remains unclear. This study compared cognition among children with NF1 and OPG (NF1 + OPG), children with NF1 without OPG (NF1-only), and children with central nervous system (CNS) tumors of the visual system without NF1 (CNS-V), to evaluate whether OPG confers additional cognitive risk beyond NF1. METHOD: This retrospective clinical cohort study included 98 pediatric patients referred for a clinical neuropsychological evaluation: 69 NF1-only, 21 NF1 + OPG, and 8 CNS-V tumor. Intellectual functioning, verbal reasoning, visuospatial reasoning, working memory, and processing speed were examined. Group differences were analyzed using one-way analyses of variance; chi-square tests assessed impairment rates. RESULTS: Children with NF1 with and without OPG did not differ significantly across cognitive domains. Both NF1 groups (NF1-only and NF1 + OPG) demonstrated weaker verbal and visuospatial reasoning abilities compared to the CNS-V group. In contrast, children with CNS-V tumors performed within the average range across domains with significantly stronger intellectual performance than both NF1 groups. CONCLUSIONS: OPG does not appear to exacerbate cognitive vulnerability in children with NF1. Cognitive weaknesses in NF1 likely reflect the underlying genotype rather than added tumor burden. Comparatively, children with non-NF1 visual system tumors demonstrated average performance. These findings underscore the importance of routine neuropsychological monitoring in children with NF1 regardless of tumor status and highlight the need for prospective, adequately powered studies to further disentangle genotype- and tumor-related effects.